Hello [NAME OF REPRESENTATIVE],

I appreciate you taking the time to speak with me about pulmonary arterial hypertension, the importance of access to sotatercept (Winrevair™) in Québec, and our disappointment with INESSS’ recommendation against public funding for sotatercept despite its therapeutic benefits.

Negotiating prices is the only way to improve sotatercept’s cost effectiveness. We hope the Minister of Health will, despite the INESS recommendation, join with the pCPA in price negotiations for sotatercept.

I want to thank you for your willingness to reach out to the Minister of Health on this important issue on behalf of people living with pulmonary arterial hypertension. Please find attached a draft letter, which you are welcome to customize and send to the Minister. I would appreciate it if you could copy me on the letter when you send it.

In the meantime, if you have any questions, please feel free to reach out to me or to the Pulmonary Hypertension Association of Canada directly at [info@phacanada.ca](mailto:info@phacanada.ca).

Sincerely,

[NAME]